Core Insights - A total of 81 stocks received buy ratings from institutions today, with 16 stocks receiving initial coverage [1] - The mechanical equipment sector is the most favored, with 13 stocks listed in the buy rating report, followed by the pharmaceutical and food & beverage sectors with 11 and 7 stocks respectively [2] Institutional Ratings - 84 buy rating records were published today, with 24 records providing future target prices; 18 stocks have an upside potential exceeding 20% [1] - The highest upside potential is for Aofei Data, with a target price of 29.78 yuan, indicating a 59.00% upside; other notable stocks include ZTE Corporation and Huicheng Co., with upside potentials of 51.35% and 46.13% respectively [1] - Among the stocks rated today, 16 received initial attention from institutions, including Aimeike and BeiGene [1] Market Performance - Stocks with buy ratings averaged a decline of 0.77%, underperforming the Shanghai Composite Index; 33 stocks saw price increases, with the largest gains from BeiGene, Century Huatong, and Zhongji Xuchuang, which rose by 5.62%, 5.11%, and 5.06% respectively [1] - Stocks with significant declines included Aters, Longi Green Energy, and Yisheng Magic, with drops of 14.33%, 7.35%, and 6.47% respectively [1] Sector Analysis - The mechanical equipment industry is highlighted as the most attractive, with key stocks like Yizhim and Juxing Technology receiving buy ratings [2] - The pharmaceutical and food & beverage sectors also garnered attention, with 11 and 7 stocks respectively making it to the buy rating list [2]

Core Points - The average stock price of A-shares is 13.93 yuan, with 20 stocks priced below 2 yuan, the lowest being *ST Yuan Cheng at 0.58 yuan [1] - As of November 12, the Shanghai Composite Index closed at 4000.14 points, indicating a relatively low proportion of both high-priced and low-priced stocks in the A-share market [1] - Among the low-priced stocks, 8 are ST stocks, accounting for 40% of the total [1] Low-Priced Stocks Summary - The lowest priced stock is *ST Yuan Cheng at 0.58 yuan, followed by *ST Su Wu at 0.98 yuan and *ST Jin Ke at 1.40 yuan [1] - In terms of market performance, 4 of the low-priced stocks increased in price, with Haihang Holdings, *ST Hui Feng, and *ST Su Wu showing gains of 1.09%, 1.08%, and 1.03% respectively [1] - Conversely, 12 stocks declined, with Chongqing Steel, Rongsheng Development, and Yabo Co. experiencing drops of 1.88%, 1.74%, and 1.53% respectively [1] Low-Priced Stocks Table - The table lists various low-priced stocks along with their latest closing prices, daily price changes, turnover rates, price-to-book ratios, and industries [1]

Core Points - The Shanghai Composite Index fell by 0.07% on November 12, with 11 industries experiencing gains, led by household appliances and comprehensive sectors, which rose by 1.22% and 1.05% respectively [1] - The textile and apparel industry ranked third in terms of daily gains, increasing by 0.87% [2] - The overall market saw a net outflow of 58.897 billion yuan, with the pharmaceutical and banking sectors attracting the most inflow of 2.402 billion yuan and 1.810 billion yuan respectively [1] Industry Summary Textile and Apparel Industry - The textile and apparel sector had a daily increase of 0.87%, with 59 out of 105 stocks rising, including 7 hitting the daily limit [2] - The leading stock in terms of net inflow was Seven Wolves, with a net inflow of 183 million yuan, followed by Xinha and Jiumuwang with inflows of 53.176 million yuan and 41.275 million yuan respectively [2] - The sector also saw a net outflow of 504,100 yuan, with 17 stocks experiencing significant outflows, led by Wanlima with a net outflow of 126.504 million yuan [3] Key Stocks in Textile and Apparel - Top inflow stocks included: - Seven Wolves: +7.39%, 14.47% turnover, 183 million yuan inflow - Xinha: +4.94%, 10.66% turnover, 53.176 million yuan inflow - Jiumuwang: +10.05%, 3.58% turnover, 41.275 million yuan inflow [2] - Top outflow stocks included: - Wanlima: -5.39%, 29.61% turnover, -126.504 million yuan outflow - Yunzhi: -9.50%, 10.87% turnover, -46.626 million yuan outflow - Cuihua Jewelry: -2.01%, 7.48% turnover, -29.524 million yuan outflow [3]

资金面上看，两市主力资金全天净流出588.97亿元，今日有5个行业主力资金净流入，医药生物行业主 力资金净流入规模居首，该行业今日上涨0.61%，全天净流入资金24.02亿元，其次是银行行业，日涨幅 为0.50%，净流入资金为18.10亿元。 主力资金净流出的行业有26个，电力设备行业主力资金净流出规模居首，全天净流出资金177.43亿元， 其次是计算机行业，净流出资金为67.11亿元，净流出资金较多的还有电子、基础化工、机械设备等行 业。 医药生物行业今日上涨0.61%，全天主力资金净流入24.02亿元，该行业所属的个股共477只，今日上涨 的有302只，涨停的有11只；下跌的有168只。以资金流向数据进行统计，该行业资金净流入的个股有 252只，其中，净流入资金超亿元的有10只，净流入资金居首的是众生药业，今日净流入资金4.36亿 元，紧随其后的是中源协和、济民健康，净流入资金分别为2.20亿元、2.09亿元。医药生物行业资金净 流出个股中，资金净流出超5000万元的有10只，净流出资金居前的有合富中国、向日葵、福瑞股份，净 流出资金分别为1.41亿元、1.16亿元、7856.81万元。（数据宝） 医药生 ...

Core Insights - The pharmaceutical and biological industry saw the highest net inflow of capital today, amounting to 2.402 billion yuan, with a price change of 0.61% and a turnover rate of 2.54% [1] - The electric equipment industry experienced the largest net outflow of capital, totaling -17.743 billion yuan, with a price change of -2.10% and a turnover rate of 5.82% [2] Industry Summary - **Pharmaceutical and Biological**: - Trading volume: 6.968 billion shares - Change in trading volume: +14.69% - Net capital inflow: 2.402 billion yuan [1] - **Banking**: - Trading volume: 4.558 billion shares - Change in trading volume: +55.56% - Net capital inflow: 1.810 billion yuan [1] - **Petroleum and Chemical**: - Trading volume: 2.390 billion shares - Change in trading volume: +40.68% - Net capital inflow: 0.476 billion yuan [1] - **Electric Equipment**: - Trading volume: 14.641 billion shares - Change in trading volume: +4.29% - Net capital outflow: -17.743 billion yuan [2] - **Automobile**: - Trading volume: 5.188 billion shares - Change in trading volume: -7.75% - Net capital outflow: -3.000 billion yuan [2] - **Computer**: - Trading volume: 5.115 billion shares - Change in trading volume: -7.21% - Net capital outflow: -6.711 billion yuan [2]

新 股 研 究 北证 50 震荡回落，沪深北三市交易活跃 度均有所下降 ——北交所周报（2025 年 11 月第 2 周） 本报告导读： 11 月第 2 周沪深北三市交易活跃度均有所下降，市场主要指数除中证 500 和北证 50 指数外均有所上涨，北证 50 指数自 10 月 29 日大幅上涨后震荡回落，单周下跌 3.79%。当周北交所 1 只股票招股，2 只新股上市。 投资要点： | 请务必阅读正文之后的免责条款部分 | | --- | 新股研究 /[Table_Date] 2025.11.12 | [Table_Authors] | | | --- | --- | | | 王政之(分析师) | | | 021-38674944 | | | wangzhengzhi@gtht.com | | 登记编号 | S0880517060002 | | | 施怡昀(分析师) | | | 021-38032690 | | | shiyiyun@gtht.com | | 登记编号 | S0880522060002 | | | 王思琪(分析师) | | | 021-38038671 | | | wangsiqi3@gtht ...

Market Overview - On November 12, A-shares experienced a "V" shaped recovery, with the Shanghai Composite Index down 0.07%, the Shenzhen Component Index down 0.36%, and the ChiNext Index down 0.39% [3] - A total of 1,758 stocks rose, while 3,563 stocks fell, indicating a challenging market environment [4] Sector Performance - The healthcare sector showed strong performance, particularly in cell immunotherapy, with stocks like Kaineng Health and Jimin Health hitting the daily limit [5] - Oil and gas stocks were also strong, with PetroChina and other related companies seeing significant gains [7] - The banking sector reached new historical highs, with Agricultural Bank of China and Industrial and Commercial Bank of China leading the charge [8] Notable Stock Movements - Kaineng Health rose by 19.94% to 8.48, while Jimin Health and Nanjing New White both increased by 10% [6] - In the oil sector, PetroChina Oilfield Services rose by 10.21% to 2.59, and Zhun Oil Co. increased by 10.01% to 9.01 [7] - Conversely, the ultra-hard materials sector faced declines, with World falling over 10% [9] Impact of News on Market Sentiment - A circulating article regarding the photovoltaic industry caused market fluctuations, leading to significant declines in solar and energy storage stocks, with Tongwei Co. hitting the daily limit down [11] - Following a statement from the China Photovoltaic Industry Association, the market for polysilicon futures rebounded, reversing earlier losses [16][13]

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to less than 35% [6][9]. Core Insights - The company reported a total revenue of 27.595 billion yuan for Q3, a year-on-year increase of 44.2%, with product revenue contributing 27.31 billion yuan, up 43.9% year-on-year. The net profit attributable to shareholders was 1.139 billion yuan, significantly improving from a net loss of 3.687 billion yuan in the same period last year [6]. - The strong growth in revenue is primarily driven by the sales of the self-developed product, Zebutinib, which achieved global sales of 7.4 billion yuan in Q3, marking a 51% year-on-year increase [6]. - The company has adjusted its revenue guidance upwards, now forecasting revenue between 36.2 billion and 38.1 billion yuan for the year, while also slightly lowering the upper limit of its R&D and operating expenses forecast [6]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology industry, with a current H-share price of 197.40 HKD and a market capitalization of 171.823 billion yuan [2]. Financial Performance - For Q3, the company achieved a revenue of 10.08 billion yuan, a 41.1% increase year-on-year, with a net profit of 690 million yuan, recovering from a loss of 810 million yuan in the previous year [6]. - The company expects net profits to turn positive in 2025, with projections of 1.97 billion yuan, followed by 3.92 billion yuan in 2026 and 6.42 billion yuan in 2027 [8]. Product Pipeline - The company is advancing several products in its pipeline, including Sotoclisib, which has received breakthrough therapy designation from the FDA, and other products in various stages of clinical trials [6]. Valuation Metrics - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.94 yuan, 3.86 yuan, and 6.32 yuan, respectively, with corresponding H-share price-to-earnings (P/E) ratios of 93, 47, and 29 [8].

Core Viewpoint - On November 12, the A-share market showed a significant disparity in stock performance, with a higher number of declining stocks compared to those that rose, indicating a bearish sentiment in the market overall [1] Group 1: Market Performance - A total of 1,630 stocks rose, while 3,416 stocks declined, and 114 stocks remained flat [1] - Excluding newly listed stocks on that day, there were 77 stocks that hit the upper limit (涨停) and 6 stocks that hit the lower limit (跌停) [1] Group 2: Industry Analysis - The stocks that reached the upper limit were primarily concentrated in the following sectors: pharmaceuticals and biotechnology, construction decoration, textiles and apparel, machinery and equipment, and electrical equipment [1]

Group 1: Hong Kong Stock Market and A+H Listings - The total amount raised from IPOs in the Hong Kong stock market has exceeded HKD 190 billion this year, ranking first among global exchanges [1] - Notable A-share companies such as CATL, Hengrui Medicine, and Haitian Flavoring have successfully listed on the Hong Kong Stock Exchange, driving the A+H listing trend [1] - As of October 21, 11 A-share companies have listed in Hong Kong this year, with 78 more in the queue, indicating a strong interest in the A+H listing model [1] - Major companies with market capitalizations exceeding RMB 100 billion, such as Luxshare Precision and Sungrow Power, are among those queued for listing [1] - The surge in A-share companies listing in Hong Kong is attributed to policy support and a recovering capital market, suggesting a long-term improvement in the structure of the Hong Kong stock market [1] Group 2: Solid-State Battery Industry - The solid-state battery sector has seen significant breakthroughs, accelerating its industrial progress [3] - Related stocks in the A-share market have experienced substantial gains this year, with funds heavily invested in solid-state battery stocks achieving impressive returns [3] - Fund institutions believe that the solid-state battery industry's development is progressing faster than market expectations, with vast potential for market scale and investment value [3] Group 3: Pharmaceutical Industry Performance - In the pharmaceutical sector, CROs and CDMOs are expected to continue their positive performance from the first half of the year [4] - Other segments such as traditional Chinese medicine, medical devices, and raw pharmaceuticals are also showing promising performance [4] - Recent data disclosures from the ESMO conference and ongoing business development transactions indicate a continued positive outlook for innovative sectors within the industry [4] Group 4: Coal and Alcohol Industry Insights - The supply and demand dynamics for thermal coal are favorable, with prices expected to continue rising due to production and transportation constraints [6] - As the heating season approaches, demand from non-electric industries is increasing, leading to heightened market activity and bullish sentiment [6] - The alcohol industry is anticipated to face significant pressure in Q3, but a gradual recovery trend is expected, presenting bottom-fishing opportunities [6] - The beer sector is experiencing stable pre-holiday stocking, but competitive intensity and regulatory impacts may pressure Q3 performance [6] Group 5: Market Trends and Indices - The Shanghai Composite Index has experienced irrational declines, highlighting the management's control over market dynamics [11] - The market is expected to favor large-cap stocks in October, with growth stocks likely to continue performing well [11] - The ChiNext Index has shown a downward trend, indicating a retreat of small-cap funds amid concerns about market peaks [11] - Commodity prices, particularly precious metals, have seen significant increases, while industrial metals have also risen due to supply disruptions [11] - The bond market has reacted to interest rate cuts, with a slight decrease in U.S. Treasury yields and a corresponding rise in domestic bonds [11]